Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
September 26 2018 - 8:30PM
Geron Corporation (Nasdaq: GERN) today announced that it will host
a conference call to provide an update on the imetelstat
collaboration with Janssen Biotech, Inc. (Janssen) on Thursday,
September 27th at 8:00 a.m. ET.
Participants may access the conference call live via telephone
by dialing domestically +1 (877) 303-9139 or internationally +1
(760) 536-5195. The passcode is 7987354. Participants are advised
to dial in at least 10 minutes prior to minimize any delay in
joining the call. A live, listen-only webcast will also be
available on the Company’s website at
www.geron.com/investors/events. If you are unable to listen to the
live call, an archived webcast will be available on the Company’s
website for 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the collaborative development of a first-in-class telomerase
inhibitor, imetelstat, in hematologic myeloid malignancies. For
more information about Geron, visit www.geron.com.
CONTACT:
Suzanne MessereInvestor and Media Relationsinvestor@geron.com
media@geron.com
CG Capital877-889-1972
Geron (NASDAQ:GERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Sep 2023 to Sep 2024